CoChat

Exendin-4 Protects against Hyperglycemia-Induced Cardiomyocyte Pyroptosis via the AMPK-TXNIP Pathway

Open access
Wei, Hong, Bu, Rui, Yang, Qinghui, Jia, Jing, Li, Tao, Wang, Qiuping, Chen, Yanjun · 2019 · Journal of Diabetes Research

The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.

Abstract

Diabetic cardiomyopathy is a common cardiac condition in patients with diabetes mellitus, which results in cardiac hypertrophy and subsequent heart failure. Chronic inflammation in the diabetic heart results in loss of cardiomyocytes and subsequentially cardiac dysfunction. Accumulated evidence implicated pyroptosis as a vital contributor to the hyperglycemia-induced cardiac inflammatory response. Exendin-4, a GLP analog, promotes survival of cardiomyocytes in cardiovascular diseases, including diabetic cardiomyopathy. However, the role of Exendin-4 in cardiac pyroptosis remains to be elucidated. Our study revealed that Exendin-4 treatment protected against heart remolding and dysfunction and attenuated cardiac inflammation in high-fat diet-fed rats. The activity of caspase-1 and production of pyroptotic cytokines were significantly inhibited by Exendin-4 treatment in the diabetic heart and in high glucose-treated cardiomyocytes as well. In an effort to understand the signaling mechanisms underlying the antipyroptotic property of Exendin-4, we found that blockade of AMPK, an oxidative stress sensor, activity diminished the antipyroptotic property of Exendin-4. Phosphorylation of AMPK resulted in degeneration of TXNIP that promoted the activation of the NLRP3 inflammasome. Exendin-4 treatment decreased the protein level of TXNIP. Moreover, RNA silencing of TXNIP mimicked the antipyroptotic actions of Exendin-4. These findings promoted us to propose a new signaling pathway mediating cardioprotective effect of Exendin-4 under hyperglycemic conditions: Exendin-4 → ROS↓ → pAMPK↑ → TXNIP↓ → caspase-1↓ → IL-1 β and IL-18↓ → pyroptosis↓. In general, our study identified Exendin-4 as a pyroptotic inhibitor protecting against hyperglycemia-induced cardiomyocyte pyroptosis via the AMPK-TXNIP pathway.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1155/2019/8905917

Cites

44 of 44 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Exendin-4 improves glucose metabolism in T2DM mouse models: (a) body weight; (b) fast blood glucose measurement; (c) plasma insulin measurement after glucose injection; (d) homeostasis model assessment; (e) intraperitoneal glucose tolerance test; (f) area under the curve for IPGTT. Values are the mean ± SEM of 7 animals per group.
Figure 1 Exendin-4 improves glucose metabolism in T2DM mouse models: (a) body weight; (b) fast blood glucose measurement; (c) plasma insulin measurement after glucose injection; (d) homeostasis model assessment; (e) intraperitoneal glucose tolerance test; (f) area under the curve for IPGTT. Values are the mean ± SEM of 7 animals per group.CC BY · PubMed Central
Figure 2 Exendin-4 prevents myocardial remolding and improves cardiac function in diabetic cardiomyopathy: (a) electrocardiogram; (b) ejection fraction; (c) fraction shorting; (d) Masson's trichrome staining of coronal cardiac sections; myocardium blue stain indicating fibrotic tissues (scale bar: 1 mm); (e) quantification of cardiac fibrosis; (f) immunofluorescence of cardiac sections (scale bar: 25 μm; green: WGA and blue: DAPI); (g) transverse area of cardiomyocytes. Values are the mean ± SEM of 5 animals per group.
Figure 2 Exendin-4 prevents myocardial remolding and improves cardiac function in diabetic cardiomyopathy: (a) electrocardiogram; (b) ejection fraction; (c) fraction shorting; (d) Masson's trichrome staining of coronal cardiac sections; myocardium blue stain indicating fibrotic tissues (scale bar: 1 mm); (e) quantification of cardiac fibrosis; (f) immunofluorescence of cardiac sections (scale bar: 25 μm; green: WGA and blue: DAPI); (g) transverse area of cardiomyocytes. Values are the mean ± SEM of 5 animals per group.CC BY · PubMed Central
Figure 3 Exendin-4 attenuates inflammatory response in the diabetic myocardium: (a) q-PRC results of inflammatory factors in the myocardium; (b–e) ELISA of proinflammatory cytokines in the heart: IL-1β (b), IL-6 (c), TGF-β (d), and TNF-α (e); (f) q-PRC quantification of IL-10 in cardiac tissues; (g) IL-10 ELISA. Values are the mean ± SEM of 3 samples per group.
Figure 3 Exendin-4 attenuates inflammatory response in the diabetic myocardium: (a) q-PRC results of inflammatory factors in the myocardium; (b–e) ELISA of proinflammatory cytokines in the heart: IL-1β (b), IL-6 (c), TGF-β (d), and TNF-α (e); (f) q-PRC quantification of IL-10 in cardiac tissues; (g) IL-10 ELISA. Values are the mean ± SEM of 3 samples per group.CC BY · PubMed Central
Figure 4 Exendin-4 inhibits diabetic cardiomyocyte pyroptosis: (a) immunohistochemistry of NLRP3, cleaved caspase-1, IL-1β, and IL-18 in the myocardium; (b, c) transcriptional activity of caspase-1 and NLRP3 in the heart (n = 3); (d, e) IL-1β and IL-18 ELISA with supernatant of cardiomyocyte culture medium; (f) Western blot of pyroptotic proteins; (g) caspase-1 activity assay (n = 3); (h) FLICA staining in cardiomyocytes. Upper panels showed the fluorescent images of CON, HG, and HG+EXE cardiomyocytes. The lower panel is a statistic of the enrichment of FLICA emitting fluorescence in single cells (n = 10).
Figure 4 Exendin-4 inhibits diabetic cardiomyocyte pyroptosis: (a) immunohistochemistry of NLRP3, cleaved caspase-1, IL-1β, and IL-18 in the myocardium; (b, c) transcriptional activity of caspase-1 and NLRP3 in the heart (n = 3); (d, e) IL-1β and IL-18 ELISA with supernatant of cardiomyocyte culture medium; (f) Western blot of pyroptotic proteins; (g) caspase-1 activity assay (n = 3); (h) FLICA staining in cardiomyocytes. Upper panels showed the fluorescent images of CON, HG, and HG+EXE cardiomyocytes. The lower panel is a statistic of the enrichment of FLICA emitting fluorescence in single cells (n = 10).CC BY · PubMed Central
Figure 5 AMPK mediates anti-pyroptotic effects of Exendin-4. (a) ROS determination by FACS. The left arrow indicated the ROS-negative population and the right pointed the positive. (b) Transcription activity of TXNIP in cardiomyocytes. (c) Western blot. (d) RNA silencing of TXNIP in cardiomyocytes. (e) IL-1β ELISA with TXNIP RNAi. (f) Caspase-1 activity assay with TXNIP RNAi. (g) Quantification of pAMPK/AMPK with CC treatment. (h) IL-1β ELISA with CC treatment. (i) Caspase-1 activity assay with CC treatment. Values are the mean ± SEM of 3 samples per group. ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.005, and ∗∗∗∗p < 0.001.
Figure 5 AMPK mediates anti-pyroptotic effects of Exendin-4. (a) ROS determination by FACS. The left arrow indicated the ROS-negative population and the right pointed the positive. (b) Transcription activity of TXNIP in cardiomyocytes. (c) Western blot. (d) RNA silencing of TXNIP in cardiomyocytes. (e) IL-1β ELISA with TXNIP RNAi. (f) Caspase-1 activity assay with TXNIP RNAi. (g) Quantification of pAMPK/AMPK with CC treatment. (h) IL-1β ELISA with CC treatment. (i) Caspase-1 activity assay with CC treatment. Values are the mean ± SEM of 3 samples per group. ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.005, and ∗∗∗∗p < 0.001.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 44 references

Cited by

See all 91

Metadata

Authors
Wei, H., Bu, R., Yang, Q., Jia, J., Li, T., Wang, Q., & Chen, Y.
Affiliations
  • Harbin Medical University (CN)
  • Peking University Shenzhen Hospital (CN)
Corresponding author
Chen, Yanjun
Venue
Journal of Diabetes Research
Publisher
Wiley
Published
2019-12-09
Volume
2019
Pages
1-13
ISSN
  • 2314-6745 (ISSN-L)
  • 2314-6753
OpenAlex
W2993303703
Cited by
91
References
44
Citations by year
2026: 4 · 2025: 14 · 2024: 17 · 2023: 12 · 2022: 24 · 2021: 15 · 2020: 5
FWCI
3.64
Type
journal article
Language
en
Open access
Locations
  • Journal of Diabetes Research (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
Project of Health Commission of Heilongjiang Province (2018068)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Inflammasome and immune disorders
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac Fibrosis and Remodeling
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
Keywords
exendin-4, cardiomyocyte pyroptosis, diabetic cardiomyopathy, hyperglycemia, AMPK, TXNIP, NLRP3 inflammasome, caspase-1, IL-1β, IL-18, oxidative stress, GLP-1 receptor agonists, cardiac inflammation, heart failure
MeSH terms
Pyroptosis, NLR Family, Pyrin Domain-Containing 3 Protein, Exenatide, Animals, Blood Glucose, Carrier Proteins, Cells, Cultured, Diabetes Mellitus, Experimental, Diabetes Mellitus, Type 2, Hypoglycemic Agents, Mice, Inbred C57BL, Phosphorylation, Thioredoxins, Signal Transduction, Biomarkers, Reactive Oxygen Species, Caspase 1, Interleukin-18, Myocytes, Cardiac, Interleukin-1beta, Incretins, AMP-Activated Protein Kinases, Diabetic Cardiomyopathies, Proteolysis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Exendin-4 Protects against Hyperglycemia-Induced Cardiomyocyte Pyroptosis via the AMPK-TXNIP Pathway. https://app.cochat.ai/papers/10.1155/2019/8905917
The paper
Wei, H., Bu, R., Yang, Q., Jia, J., Li, T., Wang, Q., & Chen, Y. (2019). Exendin-4 Protects against Hyperglycemia-Induced Cardiomyocyte Pyroptosis via the AMPK-TXNIP Pathway. Journal of Diabetes Research. https://doi.org/10.1155/2019/8905917

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.